Testing DISC-0974 for anemia in myelofibrosis or MDS
Part of Blood & lymphatic clinical trials.
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have myelofibrosis (with a certain risk score) or a lower-risk type of MDS, confirmed by a recent bone marrow biopsy.
- You have anemia, meaning your hemoglobin is below 10 g/dL or you need regular blood transfusions.
- You have not taken certain anemia treatments (like androgens, EPO, or luspatercept) in the last 28 days.
- You are not planning to have a stem cell transplant within the next 8 months.
- Your kidney and liver function are within acceptable limits based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This trial tests a new medicine called DISC-0974-201 for people with inflammatory bowel disease and anemia. It aims to see if the drug can improve anemia symptoms and is for people with mild disease activity who have not responded well to standard treatments.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
Hear when a new Myelofibrosis; Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.